Actinium Pharmaceuticals opened higher at $1.61, compared with its previous close of $1.59. In the last trading session, the stock traded between $1.53 and $1.67. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Actinium Pharmaceuticals is now worth
$ 20.22
Resulting in a loss of
$ 79.78 (79.78%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.01 (-0.31%)
Day High
$1.67
Day Low
$1.53
Day Open
$1.61
Prev Close
$1.59
Volume
3,39,978
1W Return
12.73%
1M Return
50.95%
3M Return
98.87%
6M Return
18.28%
1Y Return
20.99%
Market Cap ($ Mn)
50
PE Ratio
2.81
PB Ratio
1.05
PEG Ratio
-
ROE
-171.00%
ROCE
-65.17%
EPS (TTM)
$0.00
1 Week
12.73%
1 Month
50.95%
3 Months
98.87%
6 Months
18.28%
9 Months
41.52%
Actinium Pharmaceuticals releases ASH abstract on Actimab-A safety data
Actinium Pharmaceuticals released an ASH 2026 abstract on long-term safety of Actimab-A plus CLAG-M in relapsed/refractory AML. The study analyzes blood count recovery and delayed kidney/liver toxicities in patients surviving at least three months post-treatment. Prior ASH 2022 data showed one-year overall survival of 59% in venetoclax-treated patients and 51% in TP53-mutated AML. Findings support Actimab-A's development as a mutation-agnostic backbone for CD33-positive AML, facilitating transplant eligibility.
8 days agoActinium Pharmaceuticals stock up 9% on positive Phase 1 ATNM-400 data
Actinium Pharmaceuticals stock rose 8.85% to $1.43 on Tuesday. Trading volume hit 670,435 shares, 4.4 times the 100-day average. Phase 1 trial cleared initial 1.0 µCi/kg dose with no dose-limiting toxicities. Preclinical data shows activity in NSCLC, colorectal, and ovarian cancer models. Tumor retention aligned with Actinium-225 half-life supports dosing strategy.
23 days agoActinium Pharmaceuticals appoints Matt David as chief financial officer
Actinium Pharmaceuticals appoints Dr. Matt David as CFO. David brings over 20 years of biopharma and finance experience. Joins from CorMedix Inc., where he was EVP and Chief Business Officer. Led CorMedix through FDA approval of DefenCath in 2023.
28 days agoActinium Pharmaceuticals to present at H.C. Wainwright conference
Sandesh Seth, CEO of Actinium Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is scheduled for September 14, 2026, from 3:00 pm to 3:30 pm ET in New York. Management will be available for one-on-one investor meetings during the event. The company focuses on targeted radiotherapies for solid tumors and hematologic malignancies.
2mo agoActinium adds patents, manufacturing capacity for Actimab-A program
Actinium Pharmaceuticals strengthened its Actimab-A program with new US patents expiring in 2043 for solid tumors and expanded manufacturing capacity. The company is preparing for clinical milestones from late 2026 into 2027, supported by a broadened IP portfolio covering AML, MDS, and solid tumors.
3mo agoActinium secures max NYSE compliance period until Nov 2027
Actinium Pharmaceuticals secured the maximum available compliance period from NYSE American through November 27, 2027, after its plan was accepted on August 12, 2026. The company’s stock continues to trade under ATNM, subject to periodic review. Delisting proceedings may commence if compliance is not regained by the deadline.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Actinium Pharmaceuticals is now worth
$ 20.22
Resulting in a loss of
$ 79.78 (79.78%)
Note: Past profits do not guarantee future returns.
